Form 4: Arcus Biosciences Grants Equity to Chief Accounting Officer

Arcus Biosciences, Inc. granted 21,050 restricted stock units and 14,050 stock options to Chief Accounting Officer Alexander Azoy.

Summary

• Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, Inc., was granted 21,050 restricted stock units (RSUs) on January 23, 2026.
• These RSUs will vest in four equal annual installments, commencing on December 15, 2026, contingent on his continued employment with the company.
• Additionally, Azoy received 14,050 stock options on January 23, 2026, with an exercise price of $22.13 per share.
• These stock options will become exercisable in 48 equal monthly installments starting after January 1, 2026, also subject to his continued service.
• Following these transactions, Azoy beneficially owns 39,581 shares of common stock (including unvested RSUs) and 14,050 stock options.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation in the form of equity grants, which is generally a positive sign for executive retention and alignment of interests, but does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of restricted stock units and stock options aligns management incentives with shareholder interests.
• The vesting schedules for both RSUs and options promote long-term retention of a key executive.

Future Outlook

The grants include future vesting schedules for both RSUs and stock options, extending through December 2029 for RSUs and January 2030 for options, indicating a long-term incentive structure for the Chief Accounting Officer.

Industry Context

Equity grants to key executives are a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize talent, aligning their interests with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• The use of both restricted stock units (RSUs) and stock options is a common compensation strategy in the biotech sector, similar to practices at companies like Gilead Sciences or Amgen, which often combine time-based and performance-based equity awards.
• A four-year vesting schedule for RSUs and options, with monthly or annual installments, is typical for executive compensation packages across the industry, designed to ensure long-term commitment and retention.
• The exercise price of $22.13 for the options would typically reflect the market price of Arcus Biosciences' stock on the grant date, a standard practice to ensure options have intrinsic value only if the stock price appreciates.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant to Alexander Azoy, the Chief Accounting Officer, which is a standard related-party transaction for executive compensation.

Stakeholder Impact

• Shareholders: The equity grants aim to align the Chief Accounting Officer's interests with shareholders, potentially leading to better long-term performance. Dilution from future share issuance upon vesting/exercise is a consideration, but typical for executive compensation.
• Employees: Standard executive compensation practices can set a precedent or benchmark for other employee incentive programs.

Next Steps

• Alexander Azoy's restricted stock units will begin vesting in four equal annual installments starting December 15, 2026.
• His stock options will become exercisable in 48 equal monthly installments after January 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice and does not provide new fundamental information to warrant a change in investment recommendation. It indicates continued executive alignment but does not present a catalyst for significant price movement.

Keywords

Arcus Biosciences, RCUS, Alexander Azoy, Chief Accounting Officer, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Form 4, Executive Compensation